Nabriva Therapeutics AG (NASDAQ:NBRV) – Stock analysts at Wedbush cut their Q3 2017 earnings per share estimates for Nabriva Therapeutics AG in a research report issued to clients and investors on Wednesday. Wedbush analyst R. Driscoll now anticipates that the biotechnology company will post earnings per share of ($0.58) for the quarter, down from their previous estimate of ($0.56). Wedbush currently has a “Outperform” rating and a $13.00 price target on the stock. Wedbush also issued estimates for Nabriva Therapeutics AG’s Q4 2017 earnings at ($0.46) EPS, Q1 2018 earnings at ($0.46) EPS, Q2 2018 earnings at ($0.45) EPS, Q4 2018 earnings at ($0.46) EPS, FY2018 earnings at ($1.82) EPS, FY2019 earnings at ($1.67) EPS, FY2020 earnings at ($1.73) EPS and FY2021 earnings at ($1.12) EPS.

Other research analysts have also recently issued research reports about the stock. Cantor Fitzgerald initiated coverage on shares of Nabriva Therapeutics AG in a research report on Thursday, June 22nd. They issued a “buy” rating and a $16.00 target price for the company. Zacks Investment Research raised shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Saturday, May 27th. HC Wainwright reissued a “buy” rating on shares of Nabriva Therapeutics AG in a research note on Friday, May 12th. Finally, ValuEngine raised shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $15.43.

COPYRIGHT VIOLATION WARNING: “Q3 2017 Earnings Estimate for Nabriva Therapeutics AG (NASDAQ:NBRV) Issued By Wedbush” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/14/q3-2017-earnings-estimate-for-nabriva-therapeutics-ag-nasdaqnbrv-issued-by-wedbush.html.

Nabriva Therapeutics AG (NASDAQ NBRV) opened at 10.00 on Monday. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $12.75. The stock’s market cap is $268.38 million. The firm’s 50 day moving average price is $10.40 and its 200 day moving average price is $10.35.

Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.83) by $5.29. The firm had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.34 million.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors raised its position in shares of Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after buying an additional 7,924 shares during the period. Almanack Investment Partners LLC. raised its position in shares of Nabriva Therapeutics AG by 482.2% in the second quarter. Almanack Investment Partners LLC. now owns 907,183 shares of the biotechnology company’s stock valued at $1,633,000 after buying an additional 751,366 shares during the period. Wellington Management Group LLP raised its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of Nabriva Therapeutics AG during the fourth quarter valued at approximately $103,000. Hedge funds and other institutional investors own 56.65% of the company’s stock.

In other Nabriva Therapeutics AG news, Director George Harrison Talbot sold 325 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $100.56, for a total value of $32,682.00. Following the transaction, the director now owns 3,854 shares in the company, valued at approximately $387,558.24. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Hbm Healthcare Investments (Ca sold 8,558 shares of the company’s stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $10.96, for a total transaction of $93,795.68. Following the completion of the transaction, the insider now owns 2,591,396 shares in the company, valued at approximately $28,401,700.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 242,658 shares of company stock worth $2,641,709.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Earnings History and Estimates for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.